ChronoScale Holdings Corp: sale of Ekso and COO severance

What happened

• The filing says the Company completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc., on Sep 30, 2026.
• The filing says that on Sep 30, 2026 (the Separation Date) Jason C. Jones, the chief operating officer of Ekso, was terminated from his position effective as of the Separation Date and Ekso entered into a Severance and Release Agreement with him effective as of the Separation Date.
• The filing says Ekso and Mr. Jones agreed that Mr. Jones’s Phantom Performance-Based Restricted Stock Unit Agreement, dated Nov 5, 2025, as amended May 20, 2026, remains unchanged and in effect in accordance with its terms.

Key details

• Under the Severance Agreement, Mr. Jones is entitled to a lump-sum cash payment of $243,750, less applicable withholdings and deductions, representing 9 months of his base salary, payable on the Company’s 1st regularly scheduled payroll date following execution of the Severance Agreement.
• The Severance Agreement also provides Company-paid or reimbursed premiums for COBRA continuation coverage for Mr. Jones and his eligible dependents for up to 9 months following the Separation Date, subject to earlier termination if Mr. Jones becomes covered under a similar plan or ceases to be eligible for COBRA coverage.
• The severance benefits are subject to Mr. Jones’s general release of claims and compliance with the Severance Agreement and his continuing restrictive covenants.
• The filing says the Company filed a Withdrawal of Designation relating to 5,852 shares of Series B Convertible Preferred Stock with the Nevada Secretary of State on Sep 29, 2026; no shares of the Preferred Stock were outstanding at the time and the Withdrawal was effective upon filing.
• The filing includes a press release dated Oct 1, 2026, announcing the sale of Ekso and the expansion of an agreement with an existing AI infrastructure customer.

Why it may matter

• Item 5.02 reports the departure of an officer and the terms of his severance; Item 5.03 reports the withdrawal of the previously designated Series B Convertible Preferred Stock; Item 7.01 provides a Regulation FD disclosure via a press release.
  A filing does not show why the insider traded or why the company acted.